PDGFRB and hepatocellular carcinoma: Sorafenib could not only block tumor angiogenesis by inhibiting VEGFR-2 and PDGFR-β, but also inhibit tumor cell proliferation by blocking the Ras/Raf/MEK/ERK signaling pathway, thereby exerting a dual-inhibition, multi-target blocking anti-HCC effect (35).